Groundbreaking three-year partnership to tackle prostate cancer
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
If you are not yet an ANZUP member then join our large
multidisciplinary network of urogenital and prostate cancer
researchers, clinicians, nurses, psychologists, scientists, allied
health and consumer representatives. Membership is free.
If you are a member of the community and would like to learn more about below the belt cancers, then join ‘Friends of ANZUP’.
All of the major milestones in controlling cancer worldwide have
come through clinical trials, but we still have a long way to go to
help every person affected, at risk or diagnosed with this disease.
We have clinical trials across each cancer type, in various stages
of progress: in activation, open to patient recruitment, in follow
up and completed trials.
Telehealth and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations.
Teleheath and Teletrials
Teletrials builds on the telehealth model and increases access to clinical trials for people with cancer living in rural and remote locations, or in self-isolation due to COVID-19. Teletrials also allows trials recruitment and activity to continue.
Very excited to announce a land-mark new partnership between @ANZUPTrials & @PCFA which will accelerate research to improve the lives of Australian’s with #prostatecancer! Thanks to the generosity of the community to enable this partnership! @Prof_IanD https://ow.ly/Pihe50TJjJ6
2Congrats to Study Chair @DrBenTran & the team for recruiting their 150th patient (by site PI Dr Orlaith Heron at @HNZSouthern - Dunedin Hospital) on the @ANZUPtrials #TesticularCancer translational study #CLIMATE - reaching 75% recruitment! @WEHI_research @ciaraconduit @Prof_IanD
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.
Prostate Cancer Foundation of Australia (PCFA) and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) have agreed to a landmark three-year
New research findings of the ENZAMET (ANZUP 1304) study, led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), reveal that
Lutetium-177 PSMA-617 – or LuPSMA – therapy had been shown in previous clinical trials to extend lives, and improve quality-of-life, in patients with advanced metastatic